Ketorolac versus morphine for severe pain

Jelinek, George A
November 2000
BMJ: British Medical Journal (International Edition);11/18/2000, Vol. 321 Issue 7271, p1236
Academic Journal
Editorial. Compares the effectiveness of morphine and ketorolac trometamol as pain killers. Side effects associated with morphine; Indications that ketorolac trometamol is as effective as morphine with fewer side effects; Details on ketorolac including the findings of clinical studies; Reasons that ketorolac may reduce the overall cost of treatment.


Related Articles

  • Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial. Rainer, Timothy H; Jacobs, Philip; Ng, Y C; Cheung, N K; Tam, Michael; K W Lam, Peggo; Wong, Robert; Cocks, Robert A // BMJ: British Medical Journal (International Edition);11/18/2000, Vol. 321 Issue 7271, p1247 

    Objectives: To investigate the cost effectiveness of intravenous ketorolac compared with intravenous morphine in relieving pain after blunt limb injury in an accident and emergency department.Design: Double blind, randomised, controlled study and cost consequences analysis.Setting: Emergency...

  • Moraxen.  // Royal Society of Medicine: Medicines;2002, p375 

    This article presents information on Moraxen, a proprietary, prescription-only preparation of the narcotic analgesic morphine sulphate from Schwarz. This drug is on the Controlled Drugs list and can be used to treat severe pain, for example in the terminally ill. It is available in the form of...

  • Meperidine.  // AHFS Consumer Medication Information;Apr2018, p1 

    Meperidine is used to relieve moderate to severe pain. Meperidine is in a class of medications called narcotic analgesics, a group of pain medications similar to morphine. It works by changing the way the body senses pain.

  • PARAVERTEBRAL ROPIVACAINE 0.5 PERCENT VERSUS SALINE INFILTRATION ON POSTOPERATIVE PAIN SCORES AND REQUIREMENT OF RESCUE ANALGESIC. Bhat, Imran; Ganie, Farooq Ahmad; Velayat, Buch; Maqbool, Asif; Farooqi, Ayaz // Journal of Pharmaceutical & Scientific Innovation;Jul/Aug2013, Vol. 2 Issue 4, p82 

    This study was designed to determine whether ropivacane decreases the severity of acute post-thoracotomy pain scores and whether ropivacane decreases the dosage and need of rescue analgesics in comparison with placebo. In our study Patients were randomly assigned in a blinded fashion to receive...

  • High concentrations of morphine sensitize and activate mouse dorsal root ganglia via TRPV1 and TRPA1 receptors. Forster, Alexander B.; Reeh, Peter W.; Messlinger, Karl; Fischer, Michael J. M. // Molecular Pain;2009, Vol. 5 Issue 1, Special section p1 

    Background: Morphine and its derivatives are key drugs in pain control. Despite its well-known analgesic properties morphine at high concentrations may be proalgesic. Particularly, short-lasting painful sensations have been reported upon dermal application of morphine. To study a possible...

  • Inhibition of morphine tolerance is mediated by painful stimuli via central mechanisms. Iwai, Shigeki; Kiguchi, Norikazu; Kobayashi, Yuka; Fukazawa, Yohji; Saika, Fumihiro; Ueno, Keiko; Yamamoto, Chizuko; Kishioka, Shiroh // Drug Discoveries & Therapeutics;Feb2012, Vol. 6 Issue 1, p31 

    Tolerance to morphine analgesia following repeated administration disturbs the continuation of opioid therapy for severe pain. Emerging evidence suggests that the development of morphine tolerance may be antagonized by painful stimuli. To clarify the detailed mechanisms of these phenomena, we...

  • FDA Approves New Concentration of Oral Morphine Solution.  // Journal of Gerontological Nursing;Mar2010, Vol. 36 Issue 3, p5 

    The author reports that the use of morphine sulfate oral solution has been approved by the U.S. Food and Drug Administration (FDA) for use in opioid-tolerant patients in the treatment of moderate to severe acute and chronic pain.

  • Long-acting opioid for continuous pain relief.  // Clinical Advisor;Nov2009, Vol. 12 Issue 11, p16 

    The article offers new drug information on Embeda, a long-acting opioid indicated for severe pain management from King Pharmaceuticals Inc. The drug comprises pellets of an extended-release formulation of morphine enveloping the core of naltrexone. It is stated that naltrexone is designated to...

  • AcelRx Moving Sublingual Analgesic Toward Goal Line. Powers, Marie // BioWorld Today;11/16/2012, Vol. 23 Issue 224, p1 

    The article details the results of the Phase III study of AcelRx Pharmaceuticals Inc.'s Sufentanil Nanotab PCA (patient-controlled analgesia) System (ARX-01). The study found that this combination drug/device met its primary endpoint of noninferiority (p <0.001> in patient global assessment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics